Reverted Product definition

Reverted Product has the meaning set forth in Section 10.4(c).
Reverted Product means any Product containing any of the following:
Reverted Product has the meaning set forth in Section 10.4(c). Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Examples of Reverted Product in a sentence

  • Sunesis shall use Commercially Reasonable and Diligent Efforts to develop and commercialize each Reverted Product.

  • At the request of Intrexon, ZIOPHARM shall transfer to Intrexon, all quantities of Reverted Product (including API or work-in-process) in the possession of ZIOPHARM or its Affiliates.

  • Sunesis agrees to keep Biogen Idec fully informed regarding the development and commercialization activities with respect to each Reverted Product, including by providing Biogen Idec with reports at least quarterly regarding ongoing activities being undertaken with respect to Reverted Products.

  • At the request of Intrexon, Fibrocell shall transfer to Intrexon all quantities of Reverted Product (including active pharmaceutical ingredient or work-in-process) in the possession of Fibrocell or its Affiliates.

  • At the request of Intrexon, AquaBounty shall transfer to Intrexon all quantities of Reverted Product (including final products or work-in-process) in the possession of AquaBounty or its Affiliates.


More Definitions of Reverted Product

Reverted Product means any Product and Licensed CAR.
Reverted Product means any Licensed Product containing (or that is) a Licensed Antibody for which: [***]. Notwithstanding the foregoing, if a Licensed Product described in the immediately preceding sentence is a Combination Product, a product containing only the Licensed Antibody within such Combination Product shall be deemed a Reverted Product, but the Combination Product shall not be deemed a Reverted Product.
Reverted Product has the meaning set forth in Section 14.1(h).
Reverted Product means any and all of the following: (a)(i) a Program Antibody or Program Antisense Compound that acts through a Reverted Target, or (ii) a Program Protein that is encoded by a Reverted Target, including, in each such case, any such Program Antibody, Program Antisense Compound or Program Protein that had been selected by Schering-Plough for Development as a Collaboration Product; and (b) any other Antibody, Antisense Compound or Protein that is claimed in a Program Patent Right and that has been developed or acquired by Lexicon after such target has been designated a Reverted Target.
Reverted Product means all CTMs, Target Binders, Standalone Target Binders and Development Candidates (and backups thereto) that are Directed To a Reverted Target, but in each case excluding any [*] and any CTMs comprising a [*].
Reverted Product means all CTMs, Target Binders, Standalone Target Binders and Development Candidates (and backups thereto) that are Directed To a Reverted Target, but in each case excluding any [*] and any CTMs comprising a [*]; provided, however, for clarity, if the [*] becomes a Reverted Target, then Reverted Products shall include all Collaboration [*] that are: (a) derived by [*] from Target Binders [*]; or (b) identified or developed by [*] using (i) [*] or (ii) [*]. (d) A new Section 1.246 is hereby added to the Agreement which shall provide as follows: 1. 246 “Amended [*] Research Plan” means the amended Research Plan for the [*], attached as Exhibit A to Amendment No. 5 to the Agreement, as such plan may be further amended from time to time in accordance with this Agreement. (e) A new Section 1.247 is hereby added to the Agreement which shall provide as follows: 1. 247 “Collaboration [*]” means [*]. (f) A new Section 1.248 is hereby added to the Agreement which shall provide as follows: 1. 248 “Collaboration [*]” means each [*]. (g) A new Section 1.249 is hereby added to the Agreement which shall provide as follows: 1. 249 “[*] Sanofi Background IP” means Background IP Controlled by Sanofi consisting solely of: (a) Patents covering inventions that (i) were conceived or reduced to practice on or before [*] for the [*] (even if such Patents were applied for or issued after such date), (ii) are [*] into a Collaboration [*] or [*] pursuant to Section 2.9.1 (Information Sharing), and (iii) [*], pursuant to Section 17.7.2 (Reversion); and (b) Know-How that (i) was in existence on or before [*] for the [*], (ii) is [*] under Part 2 ([*]) of the [*] and that [*] pursuant to Section 2.9.1 (Information Sharing), and (iii) [*] to Research, Develop, Manufacture, or Commercialize a Reverted Product that is Directed To the [*]. [*].
Reverted Product means all CTMs, Target Binders, Standalone Target Binders and Development Candidates (and backups thereto) that are Directed To a Reverted Target, but in each case excluding any [*] and any CTMs comprising a [*]; provided, however, for clarity, if the [*] becomes a Reverted Target, then Reverted Products shall include all Collaboration [*] that are: (a) derived by [*] from Target Binders [*]; or (b) identified or developed by [*] using (i) [*] or (ii) [*]. (d) Section 1.212 of the Agreement is hereby deleted in its entirety and replaced with the following: